
Positive Phase II results for AI-created pulmonary fibrosis drug
Insilico Medicine reports improvement in patients with idiopathic pulmonary fibrosis (IPF) in a Phase IIa trial of ISM001-055. The drug, developed using generative AI, targets TNIK (Traf2- and NCK- interacting kinase) for the treatment of IPF. The topline results demonstrate that ISM001-055 is… Read More













